{"id":66939,"date":"2026-06-01T14:28:00","date_gmt":"2026-06-01T06:28:00","guid":{"rendered":"https:\/\/flcube.com\/?p=66939"},"modified":"2026-06-01T14:28:00","modified_gmt":"2026-06-01T06:28:00","slug":"abbvies-venclyxto-receives-european-commission-approval-for-two-novel-fixed-duration-combinations-in-first-line-cll-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66939","title":{"rendered":"AbbVie&#8217;s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AbbVie (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>)<\/strong> announced that the <strong>European Commission (EC)<\/strong> has granted an <strong>expanded marketing authorization<\/strong> for <strong>VENCLYXTO (venetoclax)<\/strong> to include two novel combination regimens for the treatment of <strong>adult patients with previously untreated chronic lymphocytic leukemia (CLL)<\/strong>. The approval encompasses <strong>venetoclax in combination with acalabrutinib<\/strong> (with or without obinutuzumab) and <strong>venetoclax in combination with ibrutinib<\/strong>, establishing fixed-duration, chemotherapy-free treatment options supported by robust Phase 3 clinical data demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to standard chemoimmunotherapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Label expansion<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>AbbVie (NYSE: ABBV)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>VENCLYXTO (venetoclax)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Previously untreated chronic lymphocytic leukemia (CLL)<\/td><\/tr><tr><td><strong>Approved Combinations<\/strong><\/td><td>1. Venetoclax + acalabrutinib (\u00b1 obinutuzumab)<br>2. Venetoclax + ibrutinib<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>29 May 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-supporting-approvals\" class=\"wp-block-heading\">Clinical Evidence Supporting Approvals<\/h2>\n\n\n\n<h3 id=\"h-venetoclax-acalabrutinib-obinutuzumab\" class=\"wp-block-heading\">Venetoclax + Acalabrutinib (\u00b1 Obinutuzumab)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Supporting Trial:<\/strong> Phase 3 <strong>AMPLIFY study<\/strong><\/li>\n\n\n\n<li><strong>Comparison:<\/strong> Superior to standard <strong>chemoimmunotherapy<\/strong><\/li>\n\n\n\n<li><strong>Regimen Type:<\/strong> <strong>Fixed-duration<\/strong> combination therapy<\/li>\n\n\n\n<li><strong>Key Benefit:<\/strong> Eliminates need for continuous treatment while maintaining efficacy<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-venetoclax-ibrutinib\" class=\"wp-block-heading\">Venetoclax + Ibrutinib<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Supporting Trials:<\/strong> Phase 3 <strong>GLOW<\/strong> and Phase 2 <strong>CAPTIVATE<\/strong> studies<\/li>\n\n\n\n<li><strong>Outcomes:<\/strong> Demonstrated significant improvements in both <strong>progression-free survival (PFS)<\/strong> and <strong>overall survival (OS)<\/strong> compared to control groups<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Treatment-na\u00efve CLL patients across diverse risk profiles<\/li>\n\n\n\n<li><strong>Treatment Duration:<\/strong> Fixed-duration approach reducing long-term toxicity burden<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Venetoclax<\/strong> \u2013 first-in-class, highly selective <strong>B-cell lymphoma-2 (BCL-2) protein inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Global Status:<\/strong> Approved in <strong>more than 80 countries<\/strong> across multiple hematologic malignancies<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Restores apoptosis (programmed cell death) in cancer cells by inhibiting BCL-2, a key survival protein overexpressed in CLL<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Synergistic effects when paired with <strong>Bruton&#8217;s tyrosine kinase (BTK) inhibitors<\/strong> (acalabrutinib and ibrutinib), targeting complementary pathways in CLL pathogenesis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The EC approval significantly strengthens AbbVie&#8217;s position in the European CLL market, which represents approximately <strong>30% of global CLL incidence<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Paradigm Shift:<\/strong> Moves first-line CLL treatment from <strong>continuous therapy<\/strong> to <strong>fixed-duration regimens<\/strong>, improving quality of life and reducing long-term costs<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Establishes venetoclax as the backbone of choice for combination therapy in treatment-na\u00efve CLL<\/li>\n\n\n\n<li><strong>Franchise Expansion:<\/strong> Leverages venetoclax&#8217;s established safety profile and physician familiarity across multiple indications<\/li>\n\n\n\n<li><strong>Revenue Impact:<\/strong> Analysts estimate potential <strong>\u20ac800 million\u2013\u20ac1.2 billion in peak annual European sales<\/strong> from these new combinations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This label expansion represents a major advance for European CLL patients who can now access highly effective, fixed-duration treatment options that eliminate the need for chemotherapy and continuous therapy,&#8221; said Dr. Mohamed Zaki, Executive Vice President, Research &amp; Development, AbbVie. &#8220;The robust clinical data supporting both combinations demonstrate our commitment to redefining standards of care in hematologic malignancies.&#8221;<\/p>\n\n\n\n<h2 id=\"h-commercial-outlook\" class=\"wp-block-heading\">Commercial Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">AbbVie expects immediate availability of both combination regimens across EU member states, with pricing negotiations underway with national health authorities. The company plans to leverage its established hematology commercial infrastructure and strong relationships with CLL treating physicians to drive rapid adoption.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial launches, and market opportunities for VENCLYXTO. Actual results may differ due to market adoption patterns, pricing negotiations, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66940,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[234,853,15],"class_list":["post-66939","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-abbvie","tag-nyse-abbv","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie&#039;s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization for VENCLYXTO (venetoclax) to include two novel combination regimens for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The approval encompasses venetoclax in combination with acalabrutinib (with or without obinutuzumab) and venetoclax in combination with ibrutinib, establishing fixed-duration, chemotherapy-free treatment options supported by robust Phase 3 clinical data demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to standard chemoimmunotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66939\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie&#039;s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment\" \/>\n<meta property=\"og:description\" content=\"AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization for VENCLYXTO (venetoclax) to include two novel combination regimens for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The approval encompasses venetoclax in combination with acalabrutinib (with or without obinutuzumab) and venetoclax in combination with ibrutinib, establishing fixed-duration, chemotherapy-free treatment options supported by robust Phase 3 clinical data demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to standard chemoimmunotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66939\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T06:28:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie&#8217;s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment\",\"datePublished\":\"2026-06-01T06:28:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939\"},\"wordCount\":503,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0102.webp\",\"keywords\":[\"AbbVie\",\"NYSE: ABBV\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66939#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66939\",\"name\":\"AbbVie's VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0102.webp\",\"datePublished\":\"2026-06-01T06:28:00+00:00\",\"description\":\"AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization for VENCLYXTO (venetoclax) to include two novel combination regimens for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The approval encompasses venetoclax in combination with acalabrutinib (with or without obinutuzumab) and venetoclax in combination with ibrutinib, establishing fixed-duration, chemotherapy-free treatment options supported by robust Phase 3 clinical data demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to standard chemoimmunotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66939\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0102.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie's VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66939#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie&#8217;s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie's VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization for VENCLYXTO (venetoclax) to include two novel combination regimens for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The approval encompasses venetoclax in combination with acalabrutinib (with or without obinutuzumab) and venetoclax in combination with ibrutinib, establishing fixed-duration, chemotherapy-free treatment options supported by robust Phase 3 clinical data demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to standard chemoimmunotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66939","og_locale":"en_US","og_type":"article","og_title":"AbbVie's VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment","og_description":"AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization for VENCLYXTO (venetoclax) to include two novel combination regimens for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The approval encompasses venetoclax in combination with acalabrutinib (with or without obinutuzumab) and venetoclax in combination with ibrutinib, establishing fixed-duration, chemotherapy-free treatment options supported by robust Phase 3 clinical data demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to standard chemoimmunotherapy.","og_url":"https:\/\/flcube.com\/?p=66939","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T06:28:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66939#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66939"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie&#8217;s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment","datePublished":"2026-06-01T06:28:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66939"},"wordCount":503,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66939#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0102.webp","keywords":["AbbVie","NYSE: ABBV","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66939#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66939","url":"https:\/\/flcube.com\/?p=66939","name":"AbbVie's VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66939#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66939#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0102.webp","datePublished":"2026-06-01T06:28:00+00:00","description":"AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization for VENCLYXTO (venetoclax) to include two novel combination regimens for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The approval encompasses venetoclax in combination with acalabrutinib (with or without obinutuzumab) and venetoclax in combination with ibrutinib, establishing fixed-duration, chemotherapy-free treatment options supported by robust Phase 3 clinical data demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to standard chemoimmunotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66939#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66939"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66939#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0102.webp","width":1080,"height":608,"caption":"AbbVie's VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66939#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie&#8217;s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66939"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66939\/revisions"}],"predecessor-version":[{"id":66941,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66939\/revisions\/66941"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66940"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}